<DOC>
	<DOC>NCT00407173</DOC>
	<brief_summary>This study is an open-label, single-dose, parallel group study to evaluate the effects of age and gender on the pharmacokinetics, safety, and tolerability of HCV-796 administered orally to healthy subjects.</brief_summary>
	<brief_title>Study to Evaluate the Effects of Age &amp; Gender on PK, Safety &amp; Tolerability of HCV-796 Administered to Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion: Men or nonlactating and nonpregnant women, aged 18 to 45, and &gt;65 years. Men must agree to practice barrier contraception for 12 weeks after the last test article administration. Estimated (calculated) creatinine clearance must be within the ageappropriate normal range. Exclusion: History of seizures. History of rhabdomyolysis. History of thyroid disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>